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Long-term retention of gadolinium in the skin
of rodents following the administration
of gadolinium-based contrast agents
Abstract Several publications sug-
gest a potential association between
the administration of Gadolinium-
based contrast agents (GBCAs) and
the onset of a rare but serious disease,
Nephrogenic Systemic Fibrosis
(NSF). The aim of this study was to
determine the elimination time-course
of Gadolinium (Gd) from skin tissue
after application of GBCAs in rats.
Seven different marketed GBCAs
were injected on five consecutive days
at a dose of 2.5 mmol/kg bodyweight
into the tail vein of Han-Wistar rats
and the Gd concentrations were
determined by Inductively Coupled
Plasma Mass Spectrometry (ICP-MS)
in skin biopsies taken at various time-
points up to a year after the last
injection. Most of the administered Gd
was eliminated from the skin within a
time-period of about 2 months. How-
ever, the repeated administration of
linear GBCAs resulted in long-term
retention of a small portion of the
administered Gd in the skin tissue of
rats, with substantially higher values
observed in animals treated with non-
ionic linear agents than in those that
received ionic linear GBCAs. Fol-
lowing treatment with macrocyclic
GBCAs, Gd values in the skin were in
the same range as observed in the
controls from day 24 post-injection
onwards. In summary, we observed a
correlation between the complex sta-
bility of GBCAs and the amount of
residual Gd in the skin up to a year
after application of GBCAs.
Keywords Gadolinium-based
contrast agents . Gadolinium retention .
Skin . Nephrogenic systemic fibrosis .
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Introduction
Gadolinium-based contrast agents (GBCAs) used for
Magnetic Resonance Imaging (MRI) contain a single
paramagnetic Gd3+ ion tightly bound by a complexing
agent. On the basis of the chemical structure, GBCAs can
be divided into two distinct classes: the linear, open-chain
agents and the macrocyclic agents [1]. Each class can be
further divided into ionic and non-ionic agents. The
different classes, as well as the different agents within
each class, have different complex stabilities, i.e. propen-
sities to retain the Gd3+ ion in the complex (Table 1).
The stability of GBCAs is characterized by two
parameters, the kinetic inertia and the thermodynamic
stability. Macrocyclic GBCAs are kinetically inert to Gd
dissociation compared to linear GBCAs, as they possess a
substantially higher kinetic stability, characterized by the
dissociation half-life [2, 3]. As the estimated dissociation
half-life of macrocyclic GBCAs is over 1,000 years at
pH 7.4, the thermodynamic stability of these GBCAs,
characterized by log Ktherm and log Kcond, is of minor
relevance [3].
The linear GBCAs possess a comparatively lower kinetic
stability. For the stability of these GBCAs, the thermody-
namic stability is a more relevant factor. The non-ionic
GBCAs, such as Omniscan and OptiMARK, have a
substantially lower thermodynamic stability compared with
the ionic GBCAs, such as Magnevist or MultiHance [3].
Several publications have suggested a potential associ-
ation between the administration of GBCAs and a relatively
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new disease, Nephrogenic Systemic Fibrosis (NSF) [4, 5].
In articles based on preclinical studies we have conducted,
we have reported a correlation between the Gd concen-
tration in skin tissue and the occurrence of NSF-like skin
lesions in rats [6, 8]. In all such studies, we observed
marked differences regarding the Gd concentration in
various tissues of the animals after treatment with the
different GBCAs. The most pronounced differences were
observed in the skin. The highest Gd concentrations in skin
tissue were observed after treatment with non-ionic linear
GBCAs (Omniscan and OptiMARK). The lowest concen-
trations were observed after treatment with macrocyclic
GBCAs (Gadovist and Dotarem) [7]. It is important to note
that the measurement method (ICP-MS) used cannot dis-
tinguish between chelated and unchelatedGd. This fact led to
the hypothesis that at least part of the Gd measured 5 days
post-injection (p.i.) may still have consisted of chelated Gd,
which may potentially be eliminated from the body at a
later time-point. Therefore, the aim of this study was to
determine the elimination time-course of Gd in skin tissue
and the potential long-term retention of Gd in the skin after
application of different marketed GBCAs.
Materials and methods
Animals
Han-Wistar rats (CRL:WI [GIx/BRL/HAN]IGS BR) were
obtained from Charles River (Sulzfeld, Germany), each
weighing 210–346 g. The animals were housed with a 12 h
day/night rhythm and were given water and standard diet
(ssniff R/M-H from Sniff, Germany) ad libitum. Animals
were treated according to the German law on the protection
of animals and with permission of the state animal welfare
committee.
Study design
Six animals for each treatment groupwere selected at random
andwere treated in three experimental sets. Omniscan (set 1),
Magnevist (set 1), Gadovist (set 1), MultiHance (set 2),
ProHance (set 2), Dotarem (set 2), and OptiMARK (set 3)
and saline (set 3) were injected into a tail vein once daily
on five consecutive days at a dose of 2.5 mmolGd/kg
bodyweight (b.w.). An untreated group (set 1) was included
as a second negative control group. Skin biopsies were taken
from the backs of the animals at various time-points up
to 364 days p.i. (please refer for the different time-points
to Fig. 1) under 3.5–4% isofluran inhalation with a biopsy
punch (Biopunch 4 mm, Stiefel Laboratorium GmbH,
Offenbach Germany) and the wounds were sutured with
Vicryl rapide (Ethicon GmbH, Norderstedt Germany).
Pharmacokinetics of GBCAs in rats
To assess the pharmacokinetic parameters of GBCAs,
Omniscan, Magnevist, MultiHance and Gadovist were
Table 1 Key parameters of the chelates investigated in this study (n.a. no data available)
Trade name Generic name Structural
class















16.9 14.9 12 34 a,b 7.9a,b
OptiMARK Gadoversetamide Non-ionic
linear
16.8 15.0 28.4 25-28f n.a.
Magnevist Gadopentetate
dimeglumine
Ionic linear 22.5 18.4 0.4 5.6a-8c 0.63a,b; 1.7l
MulitHance Gadobenate
dimeglumine
Ionic linear 22.6 18.4 0 9 – 9.7 n.a.
Stability-related parameter relevant for macrocyclic agents
Dissociation half-life (in hours at pH1)
Gadovist Gadobutrol Macrocyclic 7.9d 15c 2.8h – 20i
ProHance Gadoteridol Macrocyclic 2.0d >10e 0.79c; 1.2h – 2.7j
Dotarem Gadoterate
dimeglumine
Macrocyclic 26.4d 18c 0.1k
Data sources: a[8], b[9], c[9, 10], d[2], e[11], f[12], g[13], hcalculated from [14], icalculated from [15], jcalculated from [16, 17], kcalculated
from [18], lcalculated from [19]
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injected once at a dose of 2.5 mmol/kg b.w. into the tail
vein, and blood samples were taken from the cannulated
carotid vein at various time-points p.i. (1, 3, 5, 10, 15, 30,
60, 90, 120, 180 and 240 min). The pharmacokinetic
parameters were calculated with the help of WinNonlin
(Pharsight Corporation, Montain View, Ca, USA), two-
compartment model, g=1/y2.
Gadolinium measurements
The Gd concentrations in the skin samples and serum were
determined by Inductively Coupled Plasma Mass Spec-
trometry (ICP-MS 7500a, Agilent, Waldbronn, Germany)
by measuring the most abundant isotope 158Gd. Before
drying at 90°C, the skin samples (7-22 mg) were mixed
with 50 µl of 1 µM Tb(NO3)3, serving as an internal
standard. Afterwards 50 µl concentrated HNO3 and 20 µl
H2O2 were added and heated to dissolve the tissue. The
solution was filled up to 1 ml with H2O. The lower limit of
quantification of the method is about 1 nmol/l or 0.05 nmol
Gd/g skin [20, 21]. It should be noted that this method
cannot distinguish between chelated and unchelated Gd.
Statistical evaluation
In order to calculate the areas under the curve (AUC), an
exponential function was fitted to the data points by the
help of the solver function of Excel (Microsoft Coopera-
tion, Redmond, Wa, USA). Based in this function, the daily
Gd exposure was calculated and summed up to the AUC
for the investigated period. The AUCs were used to
compare the treatment groups for which a control group
(either saline or untreated) was available, i.e. for set 1 and
set 3. The AUCs of the treatment groups were adjusted by
using the difference in AUCs of the treatment group and
the respective control.
Treatment differences were tested by a distribution-free
Kruskal-Wallis one-way analysis of variance on ranks.
Fig. 1 Gadolinium concentration in the skin biopsies taken from
animals treated with Omniscan (red diamonds), OptiMARK (orange
triangles), Magnevist (violet dots), ProHance (green circles)
Dotarem (green triangles), Gadovist (green squares) and control
animals (saline and untreated). The animals were injected on five
consecutive days with 2.5 mmolGd/kg body weight (b.w.) per
injection and the Gd concentration in the skin is given as nmolGd/g
skin
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Overall differences of the medians were tested by the
Kruskal-Wallis test, whereas pairwise differences were
tested by Dunn’s test. This distribution-free multiple
comparison test does not need the assumption of normality
and tests pairs of medians following the Kruskal-Wallis
test. The significance level is adjusted on the basis of
comparisons to keep the two-sided significance level of 5%
for each experiment. Instead of means, this test uses
average ranks. Calculations were performed using NCSS
2007 (NCSS, Kaysville, Ut, USA).
Results
For several weeks after the last injection, the Gd concen-
tration in the skin decreased substantially in all treatment
groups. About 60 days after treatment with linear GBCAs,
a plateau phase for Gd concentration was observed.
Following this phase, the Gd level decreased only
marginally during the next 304 days (Fig. 1). After
treatment with the macrocyclic GBCAs, the Gd values in
skin tissue returned to the same range as that observed in
the control animals from about day 24 post-treatment
onwards. It should be noted that we could detect small
amounts of Gd in the skin of control animals, most obvious
in the skin of the untreated animals (set 1). No macroscopic
skin changes were observed in any treatment group during
the entire course of the experiment.
The following are detailed results of all treatment groups
for selected time-points post-treatment, i.e. about 1 month
and 1 year p.i. (also see Table 2).
On day 35 p.i., the highest amount of Gd was observed
after treatment with the non-ionic linear GBCAs Omniscan
(132 ± 23 nmolGd/g skin) and OptiMARK (47 ±
5 nmolGd/g skin). Lower Gd values in the skin were
measured in animals treated with the ionic linear GBCAs
Magnevist (36 ± 6 nmolGd/g skin) and MultiHance (7 ±
1 nmolGd/g skin). Even lower Gd values were observed in
biopsies taken from animals injected with the macrocyclic
GBCAs, ProHance (1 ± 1 nmolGd/g skin), Dotarem (2 ±
1 nmolGd/g skin) and Gadovist (2 ± 1 nmolGd/g skin)
(Fig. 2a).
On day 364 p.i., the highest amount of Gd was, again,
observed after treatment with the non-ionic linear GBCAs
Omniscan (72 ± 12 nmolGd/g skin) and OptiMARK (18 ±
5 nmolGd/g skin). Lower Gd values in the skin were again
measured in animals treated with the ionic linear GBCAs
Magnevist (9 ± 2 nmolGd/g skin) and MultiHance (1.4 ±
0.4 nmolGd/g skin). For biopsies taken from animals
treated with the macrocyclic GBCAs ProHance (0.08 ±
0.02 nmolGd/g skin), Dotarem (0.22 ± 0.17 nmolGd/g
skin) and Gadovist (0.06 ± 0.03 nmolGd/g skin), the Gd
values were in the same low range and close to the
detection limit of the ICP-method as for untreated control
animals (0.06 ± 0.03 nmolGd/g skin) and saline treated
animals (0.18 ± 0.07 nmolGd/g skin) (Fig. 2d). For the Gd
values measured 2 and 6 months p.i., please refer to Fig. 2b
and c.
Statistical evaluation of the Gd concentration time-
course in the skin tissue of rats of the treatment groups
evaluated in set 1 (i.e. Omniscan, Magnevist, Gadovist,
untreated) and set 3 (OptiMARK and saline) revealed
clear differences between the various GBCAs. Figure 3
depicts the results of set 1 as box plots. No elevated Gd
values could be detected in the skin tissue of rats treated
with the macrocyclic compound, Gadovist, from day 24
onwards. However, after treatment with the three linear
GBCAs Omniscan, OptiMARK and Magnevist elevated
Gd levels in skin tissue were observed for the entire
experimental observation time, with the non-ionic linear







364 p.i. (nmol/g skin)
Percent of dose
found in the skin
at day 364 p.i.
Total exposure of the
skin to Gd (molGd/g
skin × 368 days)
Exposure of the skin to Gd
during the retention period
(molGd/g skin × 301 days)
Omniscan Non-ionic linear 191 72.2 ± 11.9 ~0.0809% 32.5 ± 4.4 24.4 ± 3.5
OptiMARK Non-ionic linear n.d. 18.2 ± 4.8 ~0.0204% 9.4 ± 0.9 7.2 ± 0.8
Magnevist Ionic linear 200 8.5 ± 1.5 ~0.0095% 7.1 ± 0.4 4.7 ± 0.3
MultiHance Ionic linear 146b 1.4 ± 0.4 ~0.0016% 2.2 ± 0.3 1.5 ± 0.2
Gadovist Macrocyclic 184 0.06 ±- 0.03 ~0.00007% 1.0 ± 0.1 0.2 ± 0.1
ProHance Macrocyclic n.d. 0.08 ± 0.02 ~0.00009% 0.6 ± 0.1 0.1 ± 0.05
Dotarem Macrocyclic n.d. 0.22 ± 0.17 ~0.00024% 0.9 ± 0.2 0.2 ± 0.08
Untreated - - 0.06 ± 0.03 - 0.1 ± 0.02 0.1 ± 0.03
Saline - - 0.18 ± 0.07 - 0.04 ± 0.01 0.03 ± 0.01
aExposure of the blood of Han-Wistar rats after the administration of dose of 2.5 mmol/kg
bNote that MultiHance is excreted up to 50% by the hepatobiliary system in rats causing a 30% reduced exposure (AUC), whereas in
humans hepatobiliary elimination is only 1-4%
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compound Omniscan, showing statistically significantly
higher Gd levels compared with the ionic linear com-
pound Magnevist.
To estimate the Gd exposure to the skin, we calculated
the AUC of the Gd values for the total observation period
(until 364 days p.i., including the injection phase), as well
as for the long-term retention period (‘plateau phase’) (63-
364 days p.i.) (Fig. 4). Again, the highest total exposure
was observed after treatment with the non-ionic linear
GBCAsOmniscan (32.5 ± 4.4molGd/g skin × 368 days and
24.4 ± 3.5 molGd/g skin × 301 days for the long-term
retention period) andOptiMARK (9.4 ± 0.9molGd/g skin ×
368 days for the total Gd exposure of the skin and 7.2 ±
0.8 molGd/g skin × 301 days for the long-term retention
period). Lower exposure of the skin to Gd was observed
after treatment with the ionic linear GBCAs Magnevist
(7.1 ± 0.4 molGd/g skin × 368 days for the total Gd
exposure of the skin and 4.7 ± 0.3 molGd/g skin × 301 days
for the long-term retention period) and MultiHance (2.2 ±
0.3molGd/g skin × 368 days for the total Gd exposure of the
skin and 1.5 ± 0.2 molGd/g skin × 301 days for the long-
term retention period).
For all macrocyclic agents total Gd exposure in the skin
(wash-out phase plus long-term retention phase) was
higher than the saline and untreated controls. For the
long-term retention period, however, exposure levels were
in the same range as the controls (Fig. 4 and Table 2).
In general, the lowest values for the total exposure and
for the exposure in the long-term retention period was
observed after treatment with the macrocyclic GBCAs.
Higher values were observed after treatment with the ionic
linear GBCAs and the highest values were observed after
treatment with the non-ionic linear GBCAs. Those
differences were significant between treatment with
macrocyclic GBCA Gadovist and the treatment with the
non-ionic linear GBCAs Omniscan and OptiMARK.
Additionally, those differences were also significant
between treatment with the non-ionic linear GBCA
Omniscan and treatment with the ionic linear GBCA
Magnevist and macrocyclic GBCA Gadovist treatment.
No statistical differences were found for the total exposure
and the long-term retention period between any other two
treatment groups.
Discussion
The aim of the study was to determine the elimination
course and a potential long-term retention of Gd in the skin
of rats after administration of different marketed GBCAs.
3Fig. 2 a–c Comparison of gadolinium concentration in the skin
biopsies taken from animals on day 35, 63, 168 and 364 p.i. after
treatment withOmniscan, OptiMARK,Magnevist,Dotarem, ProHance
and Gadovist. The animals were injected on five consecutive days with
2.5 mmolGd/kg b.w. per injection and the Gd concentration in the skin
is given as nmolGd/g skin
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Regarding the elimination of Gd in the rat skin, in the
immediate phase (wash-out phase), starting after the injec-
tion and lasting for several days (macrocyclic GBCAs) to
weeks (linear GBCAs), the Gd concentration in the skin
decreased considerably. This suggests that the Gd eliminated
in this phase is readily eliminable, i.e. most likely water
soluble and intact GBCA.
In the second phase (plateau phase), a steady-state level of
Gdwas observed, which decreased onlyminimally over time.
For the linear GBCAs we observed Gd levels well above the
level observed in control animals for up to a year after the last
Gd injection (most pronounced in animals treated with
Omniscan). For the macrocyclic GBCAs we observed the
same low Gd levels in the skin as in control animals.
It has to be noted that we detected minor amounts of Gd in
skin tissue of control animals, especially in set 1. This might
be attributed to a potential Gd contamination in our laboratory.
The level of contamination was in the same range as observed
after administration of the macrocyclics, but well below the
amount of Gd observed after administration of linear GBCAs
Fig. 4 Exposure of the skin to gadolinium (a) during the whole
experiment and (b) during the retention phase. The animals were
injected on five consecutive days with 2.5 mmolGd/kg b.w. per
injection
Fig. 3 Gadolinium concentration in the skin biopsies taken from
animals treated with three different classes of GBCAs. The boxplots
display the Gd content in the skin of treated animals after subtraction
of the average Gd content of skin tissue of the respective control
animals on the respective day and ten-times the corresponding
standard deviation (SD). The null-line is set at the average value of
Gd content of the skin of control animals plus ten-times the SD. The
animals were injected on five consecutive days with Omniscan
(upper panel), Magnevist (middle panel) and Gadovist (lower panel)
at a dose of 2.5 mmolGd/kg b.w. per injection and the Gd
concentration in the skin is given as nmolGd/g skin
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(Table 2). Those differences in background values most likely
also explain theminor differences in theGd concentration and
exposure of the skin to Gd observed after treatment with the
different macrocyclic GBCAs.
The fact that the observed Gd was retained for such a
long period in the skin of treated animals leads us to
hypothesize that the Gd may exist in a water-insoluble
state, which would make it less subject to elimination. But,
as noted before, the methods used in this experiment to
measure Gd levels could not distinguish between the
various forms of Gd. Long-term retention of Gd in tissues
has also been reported from NSF patients after multiple
Gd-enhanced MRI investigations [22].
The time-course of the Gd concentrations in the skin
(Fig. 1) and the exposure of the skin to Gd correlate with
the stability of the GBCAs.
Based on kinetic considerations, the macrocyclic GBCAs
are themost stable. In-vitro serum stability experiments could
not detect any Gd release from macrocyclic agents within 15
days [23]. In the present experiment, all three macrocyclic
GBCAs showed no long-term Gd retention in the skin tissue
of treated rats that exceeded the level observed in control
animals. All three macrocyclic agents showed virtually iden-
tical patterns of Gd elimination from the skin tissue of the
study animals, reinforcing the notion that the minute in-vitro
stability differences between the macrocyclic GBCAs are
extremely unlikely to result in relevant differences in-vivo [3].
The ionic linear GBCAs are more stable than the non-
ionic linear GBCAs [3], but both may release Gd in-vivo
under certain circumstances. However, based on the results
of in-vitro stability experiments in human serum [23] and
buffered saline solution [24], any such release is expected
to be significantly less with ionic linear agents than with
non-ionic linear agents. Likewise, in our experiment, the
Gd values observed on day 364 after the last injection of
the ionic linear compound Magnevist were about nine-
times lower compared with the treatment with the non-
ionic linear compound Omniscan.
The non-ionic linear GBCAs have the highest level of Gd
in the skin tissue of study animals in the plateau phase. Still,
only a minute proportion of the injected Gd actually is
retained in the body. The Gd values observed in the skin on
day 364 p.i. of the Omniscan-treated animals correspond to
about 0.081% of the total dose of Omniscan administered.
This small fraction of Gd may explain why earlier pharma-
cokinetic studies failed to detect any Gd retention [25]. The
difference in retainedGd betweenOmniscan andOptiMARK
treatment may be related to the difference in the amount of
excess ligand in the formulation of these two GBCAs [26].
While the difference in Gd retention is qualitatively
correlated to the stability of the respective GBCA, no such
correlation exists with the selectivity of the respective
ligand to Gd over other metal ions or the acute toxicity of
GBCAs, as indicated by LD50 values (Table 1). Such a
hypothesis has been discussed previously [8, 9]. In
contrast, our study suggests the importance of the stability
of GBCAs to minimize Gd retention and to prevent the
potential release of Gd.
This study has certain limitations. The experimental
setting can be used to evaluate the concentration of Gd
retained in rats after administration of different GBCAs
using the dosing regimen employed in this study. However,
due to significant differences in the pharmacokinetic
properties of MultiHance in rats and humans, it is not
possible to make valid, clinically relevant comparisons
between MultiHance and other GBCAs using this model.
Furthermore, as with all animal studies, caution must be
exercised when extrapolating results to humans.
As the employed method for measuring Gd cannot
distinguish between chelated and unchelated Gd, it is not
possible to determine whether the retainedGd observed in the
plateau phases after application of linear agents is chelated or
unchelated. Furthermore, the study cannot answer whether
the long-term retention of small amounts of the originally
applied Gd doses plays any role in or contributes to the
fibrosis observed in skin samples of NSF patients.
However, if Gd release plays a role in the onset of NSF,
the data from this preclinical study suggest that there are
potential differences in the risk profile for the different
marketed GBCAs, with non-ionic linear agents possibly
presenting a higher risk than the macrocyclic agents.
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